Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

  1. Lookup NU author(s)
  2. Dr Lisa Russell
  3. Professor Olaf Heidenreich
  4. Dr Julie Irving
  5. Professor Anthony Moorman
  6. Heather Morrison
  7. Dr Vikki Rand
  8. Claire Schwab
  9. Professor Christine Harrison
Author(s)Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery DS, Haferlach C, Harder L, Heidenreich O, Irving JAE, Kearney L, Nguyen-Khac F, Machado L, Minto L, Majid A, Moorman AV, Morrison H, Rand V, Strefford JC, Schwab CJ, Tonnies H, Dyer MJ, Siebert R, Harrison CJ
Publication type Article
JournalBlood
Year2009
Volume114
Issue13
Pages2688-2698
ISSN (print)0006-4971
ISSN (electronic)1528-0020
Full text is available for this publication:
We report two novel, cryptic chromosomal abnormalities in precursor B-cell acute lymphoblastic leukemia (BCP-ALL): a translocation, either t(X;14)(p22;q32) or t(Y;14)(p11;q32), in 33 patients and an interstitial deletion, either del(X)(p22.33p22.33) or del(Y)(p11.32p11.32), in 64 patients, involving the pseudoautosomal region (PAR1) of the sex chromosomes. The incidence of these abnormalities was 5% in childhood ALL (0.8% with the translocation, 4.2% with the deletion). Patients with the translocation were older (median age 16 years), whilst the patients with the deletion were younger (median age 4 years). The two abnormalities result in deregulated expression of the cytokine receptor, cytokine receptor-like factor 2, CRLF2 (also known as thymic stromal-derived lymphopoietin receptor, TSLPR). Over-expression of CRLF2 was associated with activation of the JAK-STAT pathway in cell lines and transduced primary B-cell progenitors, sustaining their proliferation and indicating a causal role of CRLF2 over-expression in lymphoid transformation. In Down Syndrome (DS) ALL and two non DS BCP-ALL cell lines, CRLF2 deregulation was associated with mutations of the JAK2 pseudokinase domain suggesting oncogenic cooperation, as well as highlighting a link between non DS ALL and JAK2 mutations.
PublisherAmerican Society of Hematology
URLhttp://dx.doi.org/10.1182/blood-2009-03-208397
DOI10.1182/blood-2009-03-208397
Actions    Link to this publication